FBI Extends Tracking of Cops' Force Without New Costs

2026-16981, Application for Relief From Disabilities Imposed by Federal Laws With Respect to the Acquisition, Receipt, Transfer, Shipment, Transportation, or Possession of Firearms

The Department of Justice ("the Department") is implementing criteria to guide determinations for granting relief from disabilities imposed by federal laws with respect to the acquisition, receipt, transfer, shipment, transportation, or possession of firearms. The criteria are designed to ensure that the fundamental right of the people to keep and bear arms is not unduly infringed, that those people granted relief are not likely to act in a manner dangerous to public safety, and that granting such relief would not be contrary to the public interest.

2026-15458, Civil Money Penalty for Actions in Contempt of an Immigration Judge's Proper Exercise of Authority

This notice of proposed rulemaking ("NPRM") would implement a provision of the Immigration and Nationality Act ("INA" or "the Act") that authorizes Immigration Judges, under regulations prescribed by the Attorney General, to sanction by civil money penalty any action (or inaction) in contempt of the proper exercise of their authority by certain individuals. The rule would: define the scope of the contempt authority; provide procedures for contempt findings, penalty determinations, and penalty payment; establish an appellate process; and implement oversight of the use of contempt authority. The rule would also make conforming changes to the grounds for practitioner discipline.

2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment

Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.

2026-10128, Revision of Applications for Manufacturing and Procurement Quotas

The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.

2026-09160, Implementing PATRIOT Act Improvements: Contraband Cigarettes and Smokeless Tobacco

Starting June 8, 2026, new rules crack down harder on illegal cigarette and smokeless tobacco sales. The government lowered the amount that counts as smuggling from 60,000 to just 10,000 cigarettes and now includes smokeless tobacco in the crackdown. Sellers and distributors must keep better records and report more info, making it tougher to dodge the law and protect honest businesses.

2026-17025, Agency Information Collection Activities; Proposed eCollection eComments Requested Extension of a Previously Approved Collection Title-STOP Match Calculation Worksheet

The Department of Justice (DOJ), Office on Violence Against Women will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

Previous: 2025-08058, Duke Energy Progress, LLC; H.B. Robinson Steam Electric Plant, Unit No. 2; Subsequent License Renewal Application

Duke Energy Progress wants to keep running the H.B. Robinson Steam Electric Plant, Unit No. 2, for 20 more years after its current license ends in 2030. This means the plant can keep providing power safely and reliably for a longer time. The Nuclear Regulatory Commission is reviewing this request to make sure everything stays safe and sound.

Next: 2025-08060, Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Supplemental Biologics License Application 761309/S-001, for COLUMVI (glofitamab) Injection; Supplemental Biologics License Application 761145/S-029, for DARZALEX FASPRO (daratumumab and hyaluronidase) Injection; New Drug Application 215793, for (mitomycin) Intravesical Solution; Supplemental New Drug Application 211651/S-013, for TALZENNA (talazoparib) Capsules

The FDA is holding a public meeting to talk about new and updated cancer drugs, including COLUMVI, DARZALEX FASPRO, mitomycin solution, and TALZENNA capsules. This meeting affects patients, doctors, and drug makers by reviewing important changes that could impact treatment options and costs. The FDA also wants your comments before making final decisions, so now’s the time to speak up!